Business Description
Amicus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03152W1099
Share Class Description:
FRA:AM6: Ordinary SharesDescription
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.56 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 2.49 | |||||
| Debt-to-EBITDA | -48.36 | |||||
| Interest Coverage | 0.29 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -0.93 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 30.7 | |||||
| 3-Year EPS without NRI Growth Rate | 23.4 | |||||
| 3-Year FCF Growth Rate | 34.3 | |||||
| 3-Year Book Growth Rate | -20.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 25.32 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.72 | |||||
| 9-Day RSI | 50.25 | |||||
| 14-Day RSI | 48.45 | |||||
| 6-1 Month Momentum % | -1.11 | |||||
| 12-1 Month Momentum % | -24.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.15 | |||||
| Quick Ratio | 2.42 | |||||
| Cash Ratio | 1.58 | |||||
| Days Inventory | 552.4 | |||||
| Days Sales Outstanding | 62.2 | |||||
| Days Payable | 137.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -0.74 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.99 | |||||
| Operating Margin % | 2.92 | |||||
| Net Margin % | -21.21 | |||||
| FCF Margin % | -6.27 | |||||
| ROE % | -71.17 | |||||
| ROA % | -13.78 | |||||
| ROIC % | 6.24 | |||||
| ROC (Joel Greenblatt) % | -16.6 | |||||
| ROCE % | -2.99 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 67.39 | |||||
| PE Ratio without NRI | 146.87 | |||||
| PEG Ratio | 5.48 | |||||
| PS Ratio | 6.04 | |||||
| PB Ratio | 16.43 | |||||
| EV-to-EBIT | -176.41 | |||||
| EV-to-Forward-EBIT | 23.39 | |||||
| EV-to-EBITDA | -343.08 | |||||
| EV-to-Forward-EBITDA | 21.82 | |||||
| EV-to-Revenue | 6.39 | |||||
| EV-to-Forward-Revenue | 4.59 | |||||
| EV-to-FCF | -99.11 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.85 | |||||
| Earnings Yield (Greenblatt) % | -0.56 | |||||
| FCF Yield % | -1.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amicus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 452.284 | ||
| EPS (TTM) (€) | -0.312 | ||
| Beta | 0.61 | ||
| Volatility % | 46.76 | ||
| 14-Day RSI | 48.45 | ||
| 14-Day ATR (€) | 0.186019 | ||
| 20-Day SMA (€) | 9.2725 | ||
| 12-1 Month Momentum % | -24.58 | ||
| 52-Week Range (€) | 8.2 - 13.2 | ||
| Shares Outstanding (Mil) | 298.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amicus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amicus Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amicus Therapeutics Inc Frequently Asked Questions
What is Amicus Therapeutics Inc(FRA:AM6)'s stock price today?
The current price of FRA:AM6 is €9.30. The 52 week high of FRA:AM6 is €13.20 and 52 week low is €8.20.
When is next earnings date of Amicus Therapeutics Inc(FRA:AM6)?
The next earnings date of Amicus Therapeutics Inc(FRA:AM6) is 2025-02-28 Est..
Does Amicus Therapeutics Inc(FRA:AM6) pay dividends? If so, how much?
Amicus Therapeutics Inc(FRA:AM6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers